Skip to content
Search

Latest Stories

pharmaceuticals

Russia's President Vladimir Putin and India's Prime Minister Narendra Modi attend the India-Russia Business Forum in New Delhi, India, December 5, 2025.
What We're Watching

Putin-Modi meeting is all show, Kyrgyzstan plummets further from democracy, Stalemate ends in Yemen’s civil war

Despite the lavish ceremony, Russian President Vladimir Putin and Indian Prime Minister Narendra Modi’s meeting produced few concrete outcomes.

Hard Numbers: Trump tariffs drugs, WarSec calls unusual meeting, Argentina’s poverty plummets, Oz man fined in deepfake porn case
What We're Watching

Hard Numbers: Trump tariffs drugs, WarSec calls unusual meeting, Argentina’s poverty plummets, Oz man fined in deepfake porn case

100: Donald Trump has announced a 100% tariff on branded pharmaceuticals for any company that is not already building new facilities in the US.

Shipping containers from China are seen at the Port of Los Angeles, in San Pedro, California, U.S., May 1, 2025.
What We're Watching

Trump says he might back off on China tariffs – but Beijing holds firm

With US-China trade grinding to a halt, President Donald Trump told ABC News on Sunday that he would lower the 145% tariff imposed on China “at some point.”

An aerial image of the Taiwan Semiconductor Manufacturing Co., Ltd. (TSMC) plant in Kikuyo Town, Kumamoto Prefecture, Japan, on March 14, 2025.
What We're Watching

Trump prepares to slap tariffs on semiconductors and pharma

The topsy-turvy-tariff tale continued to swing, as the Trump administration advanced a plan on Monday that could result in new levies on semiconductors and pharmaceuticals. The news came days after US President Donald Trump announced that smartphones would be exempt from the 145% duty that he had slapped on China.

President Joe Biden waits on stage during a White House event announcing moves to lower the prices of ten widely-used prescription drugs
News

Biden’s drug deal of the century

The Biden administration this week selected the first 10 drugs that will be subject to price negotiations between the US government and pharma companies.